Published
April 4, 2026
Three separate settlements totaling $15.26 million refund what consumers and insurers overpaid for contaminated valsartan, losartan, and irbesartan — and a single claim form covers all three.
What Is This Settlement About?
Three separate class action settlements have been reached in a massive multidistrict litigation over contaminated blood pressure medications. The lawsuit alleged that certain generic versions of valsartan, losartan, and irbesartan were manufactured using processes that created nitrosamine impurities -- NDMA, NDEA, and NMBA -- which are classified as probable human carcinogens. The contamination led to a series of nationwide drug recalls starting in 2018.These three settlements resolve the economic loss claims -- meaning they cover what consumers and insurers overpaid for drugs that were allegedly contaminated and should not have been sold. They do not cover personal injury or medical monitoring claims, which are being litigated separately in the same MDL.
All three defendants deny any wrongdoing and deny that the levels of nitrosamine impurities found in their products were harmful or carcinogenic.
Status
Claims Open
Claim Deadline
June 2, 2026
one claim form covers all three settlements
Combined Fund
$15.26 million
Hetero Valsartan ($11.37M) · Aurobindo Irbesartan ($2M) · Vivimed Losartan ($1.9M)
Proof Required
Encouraged, not always required
documentation supports larger payouts
Three Settlements, One Claim Form
There are three separate settlement funds from three different pharmaceutical companies, but they are all administered through one website with one claim deadline. Here is what each settlement covers:Hetero — Valsartan ($11,365,490): Covers individuals who purchased valsartan finished drug formulations containing Hetero Process III valsartan API, sold between May 1, 2018 and July 31, 2018. For full details on the Hetero settlement, including how to check if your pills were made by Hetero, see our in-depth Hetero Valsartan settlement page.
Aurobindo — Irbesartan ($2,000,000): Covers individuals who purchased irbesartan finished drug formulations manufactured using Aurobindo's IC Route of Synthesis, purchased from January 1, 2016 to the present.
Vivimed — Losartan ($1,899,000): Covers individuals who purchased losartan finished drug formulations sold under specific Vivimed National Drug Codes (NDCs): 23155-644-09, 23155-644-10, 23155-645-03, 23155-645-09, 23155-645-10, 23155-646-03, 23155-646-09, and 23155-646-10. For full details on the Vivimed settlement, including how to check your NDC number and what NMBA contamination means, see our in-depth Vivimed Losartan settlement page.
You may qualify for one, two, or all three settlements depending on which drugs you purchased.
Who Qualifies?
You qualify if you are an individual in the United States, its territories, or possessions who paid any amount of money for retail purchases of any of the covered drugs during the relevant time periods. This includes copays, out-of-pocket payments, and any other amount you paid. The class also includes third-party payors like health insurers and welfare funds.You do not qualify if you purchased these drugs only for resale, if you are a pharmacy benefit manager, or if you are a federal or state government entity (with limited exceptions for self-funded government employee benefit plans).
If you are not sure whether you purchased a covered drug, you can visit the settlement website and answer a few questions to check your eligibility, or call the settlement administrator.
Do I Need Proof?
Documentation should be submitted to support your claim if possible. Pharmacy receipts, insurance explanation of benefits statements, or prescription history records are all examples of documentation that could support your claim.If you submit a claim without documentation, the administrator will review it and may contact you for proof of purchase from your pharmacy. Providing documentation upfront will help prevent delays in processing your claim. But the notice does not state that documentation is absolutely required -- it says "if possible."
How Do I File a Claim?
Submit your claim online at SartanMedicationSettlement.com or download a paper claim form and mail it to the settlement administrator. Your claim must be submitted online or postmarked by June 2, 2026. Filing close to the cutoff? See our news alert, $15.26 million blood pressure drug settlement deadline (June 2, 2026), for a quick walkthrough of the single claim form that covers all three settlements.When Will Payments Be Sent?
The final approval hearing is scheduled for June 30, 2026 at 10:00 AM at Courtroom 3D of the U.S. District Court for the District of New Jersey. If the court grants final approval and no appeals are filed, the settlement administrator will begin distributing payments after the effective date. The exact timing depends on the court's final approval order and how long claims processing takes.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Official Settlement Notice (PDF)
Settlement Website: SartanMedicationSettlement.com
Submit Claim
Related Settlement Pages
• Hetero Valsartan Settlement ($11.37M) — In-depth guide to the largest of the three settlements, including how to check if your pills were made by Hetero, what NDMA is, and whether valsartan can cause cancer.• Aurobindo Irbesartan Settlement ($2M) — In-depth guide to the Aurobindo irbesartan settlement, including NDEA contamination details, IC Route of Synthesis, and class period from January 2016 to present.
• Vivimed Losartan Settlement ($1.9M) — In-depth guide to the Vivimed losartan settlement, including impacted NDC numbers, NMBA contamination details, and Heritage/Avet Pharmaceuticals coverage.
Sources
• Official Settlement Website -- SartanMedicationSettlement.com• Court-authorized settlement notices, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (D.N.J.)
• PR Newswire, "Class action settlements involving Hetero Valsartan, Aurobindo Irbesartan, and Vivimed Losartan medications" (April 2, 2026)
For more class actions keep scrolling below.
Settlement Amount
$15,264,490
three sub-settlements: Hetero Valsartan $11.37M + Aurobindo Irbesartan $2M + Vivimed Losartan $1.9M
Case Title
In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation
Case Number
1:19-md-02875-RBK-SAK
Court
U.S. District Court, District of New Jersey
Final Approval Hearing
June 30, 2026 at 10:00 a.m.
Courtroom 3D — U.S. District Court, District of New Jersey
Official Website
Sartan Medication Settlement.com
